Comments on: Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

Comments on: Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease https://insideout.vn/io-therapeutics-inc-presented-data-from-studies-of-irx4204-the-companys-phase-ii-clinical-development-stage-highly-selective-third-generation-rxr-nuclear-receptor-agonist-compound-supp/ Inside Out Wed, 10 Jul 2024 01:31:40 +0000 hourly 1 https://wordpress.org/?v=6.6.2